Quality of life assessments in advanced breast cancer: should there be more consistency?-Reference-Cited by-同舟云学术

Quality of life assessments in advanced breast cancer: should there be more consistency?

Published:2012-06-04 Issue:5 Volume:21 Page:565-580
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:

Author:

REED E.,KÖSSLER I.,HAWTHORN J.

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2354.2012.01370.x/fullpdf

Reference79 articles.

1. Dose-intensive epirubicin-based chemotherapy is superior to intensive intravenous cyclophosphamide, methotrexate and flourouracil regimen in metastatic breast cancer: a randomized multinational study;Ackland;Journal of Clinical Oncology,2001a

2. Ackland S.P. Gebski V. Wilson A. Green M. Hornery S. Dhillon H. Levi J. Van Hazel G. Simes R. Forbes J. Coates A. 2001b Proceedings of the American Society of Clinical Oncology

3. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: dose quality of life matter?;Bernhard;Journal of Clinical Oncology,1999

4. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial;Biganzoli;Journal of Clinical Oncology,2002

5. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer;Bishop;Journal of Clinical Oncology,1999

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany;Cost Effectiveness and Resource Allocation;2024-03-08

2. Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers’ Information Sources;International Journal of Technology Assessment in Health Care;2022

3. Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach;Cancers;2021-05-12

4. Desarrollo de una estrategia holística para la valoración de la calidad de vida en pacientes con cáncer de mama en las distintas etapas de la enfermedad;Psicooncología;2021-03-01

5. Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018;Health and Quality of Life Outcomes;2020-10-12